Mobile Site ›

Von Willebrand Disease (VWD)
Part 1: NHLBI Diagnosis Guidelines

Introduction & Clinical Assessment Recommendations



Introduction

Slide 1

March 2011


Welcome to Mayo Medical Laboratories' Hot Topics. These presentations provide short discussions of current topics and may be helpful to you in your practice.

Our presenter for this program is William L. Nichols, MD, consultant in the Special Coagulation Laboratory and Hemophilia Center at Mayo Clinic in Rochester, Minnesota. In Part 1 of this 2-part presentation, Dr. Nichols will provide a brief overview of von Willebrand disease (VWD) and summarize recommendations for clinical assessment for VWD, primarily based on guidelines from the National Heart, Lung, and Blood Institute expert panel.

Thank you for tuning in for Mayo Medical Laboratories' Hot Topics series on von Willebrand disease (VWD). For this first of two short presentations on VWD Diagnosis Guidelines, I will initially provide an introduction about von Willebrand factor (VWF) and hereditary VWD, as well as a summary about acquired von Willebrand syndrome (AVWS). Since VWD diagnosis involves synthesizing both clinical and laboratory assessments, I will then focus on discussing guidelines for the clinical evaluation for VWD. My discussion will be mainly based on the evidence-based guidelines from the National Heart, Lung, and Blood Institute (NHLBI) expert panel report in 2008. In the subsequent presentation (Part 2) I will focus on a discussion of guidelines for the laboratory evaluation for VWD.

Introduction

 

Jump to section:


Key